Left ventricular Diastolic dysfunction in Female Rheumatoid Arthritis Patients: Association to Insulin Resistance and Metabolic Syndrome

Title: Left ventricular Diastolic dysfunction in Female Rheumatoid Arthritis Patients: Association to Insulin Resistance and Metabolic Syndrome

Authors: Eglal M Kenawy, Mohamed M Rayan, Mona M Abdel Meguid, Asmaa I Arafa, Mohammed M Ahmed, Mahmoud Abdelsabour

DOI: https://dx.doi.org/10.18535/jmscr/v4i10.42

Abstract

References

Corresponding Author

Abstract

Background: Inflammation characteristic of active RA, likely plays a major role in cardiovascular disease Cardiac involvement (pericardial, myocardial and endocardial) is known in patients of Rheumatoid arthritis.

Aim of this work: is to investigate left ventricular diastolic dysfunction (DD) in mildly active or remittent rheumatoid arthritis female patients and its association to insulin resistance and metabolic syndrome.

Patients and Methods: A total of forty eight middle aged female patients with rheumatoid arthritis compared to thirty age and sex matched apparently healthy participants as a control group were included. According to echocardiographic findings patients were classified into two subgroups: patients without diastolic dysfunction (without DD) and patients with diastolic dysfunction (DD).

Results: We found left diastolic dysfunction was less frequent in RA patients who are controlled or nearby (DAS28 score ≤ 3.5) than reported by other previous studies 7/48 (14.6%). Patients with diastolic dysfunction had statistically significant higher serum insulin level, fasting blood sugar, TNFα, insulin resistance and metabolic syndrome than RA patient without diastolic dysfunction.

Conclusion: We found left diastolic dysfunction was less frequent in patients how are controlled or nearby (DAS28 score ≤ 3.5), with a significant association between diastolic dysfunction and presence of insulin resistance with metabolic syndrome.

Keywords: Rheumatoid Arthritis, diastolic dysfunction, insulin resistance, metabolic syndrome.

References

1. Marco I. Rheumatoid arthritis and atypical cardiovascular disease. Inflammation changing the clinical presentation. Can Fam Physician. 2013 May; 59(5): 505-509.

2. Gullick NJ, Scott DL. Co-morbidities in established rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2011;25:469-83.

3. Lindhardsen J, Ahlehoff O, Gislason GH, Madsen OR, Olesen JB, et al. The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. Ann Rheum Dis 2011;70 930:929–934. doi:10.1136/ard.2010.143396:

4. Dessein PH, Joffe BI, and Singh Sh. Biomarkers of endothelial dysfunction, cardiovascular risk factors and atheroscl-erosis in rheumatoid arthritis. Arthritis Res Ther. 2005; 7(3): R634–R643.

5. Peters MJ, Symmons DP, McCarey D, Dijkmans BA, Nicola P, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis: Ann Rheum Dis. 2010 Feb;69(2):325-31. doi: 10.1136/ard.2009.113696.

6. Semb A, Holme I., Kvien T. and Pedersen T. Intensive lipid lowering in patients with rheumatoid arthritis and previous myocardial infarction: an explorative analysis from the incremental decrease in endpoints through aggressive lipid lowering (IDEAL) trial. Rheumatology (Oxford). 2011 Feb;50(2):324-9. doi: 10.1093/rheumatology/keq295.

7. Szekanecz Z, Koch AE. Vascular involvement in rheumatic diseases: ‘vasc-ular rheumatology’. Arthritis Res Ther. 2008;10(5):224. doi: 10.1186/ar2515.

8. Sattar N, McCarey DW, Capell H, McInnes IB. Explaining how ‘high-grade’ systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003; 108:2957–63.

9. Pieringer H, Pichler M. Cardiovascular morbidity and mortality in patients with rheumatoid arthritis: vascular alterations and possible clinical implications. Q J Med 2011; Jan;104(1):13-26.

doi: 10.1093/qjmed/hcq203.

10. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, et al. 2010 Rheumatoid Arthritis Classification Criteria An American College of Rheumatology/ European League Against Rheumatism Collaborative Initiative. Ann Rheum Dis. 2010 Sep;69(9):1580-8.

doi: 10.1136/ard.2010.138461.

11. Ibrahim MM, Elamragy AA, Girgis H and Nour MA. Cut off values of waist circumference & associated cardiovascular risk in Egyptians: BMC Cardiovascular Disorders. 2011; 11:53.

DOI: 10.1186/1471-2261-11-53.

12. The IDF consensus worldwide definition of the metabolic syndrome. http://www.idf.org/webdata/docs/IDF_Meta_def_final.pdf, 2006.

13. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–2497.

14. Frier BM, Ashby JP, Nairn IM, Baird JD. Plasma insulin, C-peptide and glucagon concentrations in patients with insulin independent diabetes treated with chlorpropamide. Diab. Metab. 1981; 7(1): 45-49.

15. HOMA Calculator. http://www.dtu.ox.-ac.uk/homacalculator/index.php.

16. Seriolo B, Paolino S, Sulli A, Fasciolo D, Cutolo M. Effects of Anti-TNF- Treatment on Lipid Profile in Patients with Active Rheumatoid Arthritis. Ann N Y Acad Sci. 2006 Jun;1069:414-9.

17. Intiso D, Zarrelli MM, Lagioia G, Di Rienzo F, Checchia De Ambrosio C, et al. Tumor necrosis factor alpha serum levels and inflammatory response in acute ischemic stroke patients. Neurol Sci. 2004 Feb;24(6):390-6.

18. Ferraz-Amaro I, González-Juanatey C, López-Mejias R, Riancho-Zarrabeitia L, González-Gay MA. Metabolic Syndrome in Rheumatoid Arthritis. Mediators of Inflammation Volume 2013 (2013), Article ID710928,11pages.

19. Kerekes G, Nurmohamed MT, González-Gay MA, Seres I, Paragh G, et al. Rheumatoid arthritis and metabolic syndrome: Nat Rev Rheumatol. 2014 Nov;10(11):691-6.

doi: 10.1038/nrrheum.2014.121.

20. Chung CP, Oeser A, Solus JF, Avalos I, Gebretsadik T, et al. Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atherosclerosis. 2008 Feb;196(2):756-63.

21. Zhang J, Fu L, Shi J, Chen X, Li Y, et al. The risk of metabolic syndrome in patients with rheumatoid arthritis: a meta-analysis of observational studies. PloS One. 2013 Oct 25;8(10):e78151.

doi:10.1371/journal.pone.0078151.

22. Garcia Diaz Jde D, Lopez de Guzman A, Sivera Monzo L, Cuende Quintana E. Significance of the insulin resistance in vascular disease associated to rheumatoid arthritis. Med Clin. (Barc) 2008 Vol. 130. No. 5. Feb 197-8.

23. Stagakis I, Bertsias G, Karvounaris S, Kavousanaki M, Virla D, et al. Anti-tumor necrosis factor therapy improves insulin resistance, beta cell function and insulin signaling in active rheumatoid arthritis patients with high insulin resistance. Arthritis Res Ther. 2012 Jun 12;14(3):R141. doi: 10.1186/ar3874.

24. Fontes-Carvalho R, Ladeiras-Lopes R, Bettencourt P, Leite-Moreira A, Azevedo A. Diastolic dysfunction in the diabetic continuum: association with insulin resistance, metabolic syndrome and type 2 diabetes. Cardiovascular Diabetology 201514:4. DOI: 10.1186/s12933-014-0168-x 41.

25. Corrao S, Messina S, Pistone G, Calvo L, Scaglione R, Licata G. Heart involvement in Rheumatoid Arthritis: Systematic review and meta-analysis. Int J Cardiol. 2013 Sep 1;167(5):2031-8. doi: 10.1016/j.ijcard.2012.05.057.

26. Peterson LR, Herrero P, Schechtman KB, Racette SB, Waggoner AD, et al. Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation. 2004 May 11;109(18):2191-6.

27. Ogata T1, Miyauchi T, Sakai S, Takanashi M, Irukayama-Tomobe Y, Yamaguchi I. Myocardial fibrosis and diastolic dysfunc-tion in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferatoractivated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-B pathway. J Am Coll Cardiol. 2004 Apr 21;43(8):1481-8.

28. Anderson EA, Hoffman RP, Balon TW, Sinkey CA, Mark AL. Hyperinsulinemia produces both sympathetic neural active-tion and vasodilation in normal humans. J Clin Invest. 1991 Jun;87(6): 2246-52.

29. Park JS, Nam JS, Cho MH, Yoo JS, Ahn CW, et al. Insulin resistance independently influences arterial stiffness in normogl-ycemic normotensive postmenopausal women. Menopause. 2010;17:779–84.

30. MacIsaac RJ, Thomas MC, Panagioto-poulos S, Smith TJ, Hao H, et al. Association between intrarenal arterial resistance and diastolic dysfunction in type 2 diabetes. Cardiovasc Diabetol. 2008; 7:15.

31. Ceriello A, Taboga C, Tonutti L, Quagliaro L, Piconi L, et al. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment. Circulation. 2002;106:1211–8.

32. Kuster GM, Lancel S, Zhang J, Communal C, Trucillo MP, et al. Redox-mediated reciprocal regulation of SERCA and Na + −Ca2+ exchanger contributes to sarcoplasmic reticulum Ca2+ depletion in cardiac myocytes. Free Radic Biol Med. 2010 May 1;48(9):1182-7. doi: 10.1016/j.freeradbiomed.2010.01.038.

33. Solomon DH, Curhan GC, Rimm EB, Cannuscio CC, Karlson EW. Cardiovas-cular risk factors in women with and without rheumatoid arthritis. Arthritis Rheum. 2004 Nov;50(11):3444-9.

34. Wolfe F1, Michaud K. Effect of Body Mass Index on Mortality and Clinical Status in Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2012 Oct;64(10): 1471-9. doi: 10.1002/acr.21627.

35. Sonkusare R, Nelson SS. Diastolic dysfunction in rheumatoid arthritis. Journal of Evolution of Medical and Dental Sciences 2014; Vol. 3, Issue 17, April 28; Page: 4560-8.

36. Udayakumar N, Venkatesan S, Rajendiran C. Pulmonary hypertension in rheumatoid arthritis: relation with the duration of the disease. Int J Cardiol. 2008;127:410–2.

37. Solomon DH, Kremer J, Curtis JR, Hochberg MC, Reed G. Explaining the Cardiovascular Risk Associated with Rheumatoid Arthritis: Traditional Risk Factors Versus Markers of Rheumatoid Arthritis Severity. Ann Rheum Dis. 2010 November ; 69(11): 1920–1925.

38. Midtbø H, Gerdts E, Kvien TK, Olsen IC, Lønnebakken MT, et al. The association of hypertension with asymptomatic cardiova-scular organ damage in rheumatoid arth-ritis. Blood Press. 2016 Oct25(5):298-304.

39. Sarmiento-Monroy JC, Amaya-Amaya J, Espinosa-Serna JS, Herrera-Dıaz C, Anaya JM, Rojas-Villarraga A. Cardiovascular Disease in Rheumatoid Arthritis: A Systematic Literature Review in Latin America. Arthritis Volume 2012 (2012), Article ID 371909, 17 pages doi:10.1155/2012/371909

40. Aslam F1, Bandeali SJ, Khan NA, Alam M. Diastolic Dysfunction in Rheumatoid Arthritis: A Meta-Analysis and Systematic Review. Arthritis Care Res (Hoboken). 2013 Apr;65(4):534-43. doi: 10.1002/acr.21861.

41. ElSaid TO, Olama ShM, ELHefny AM, ElHawary GES; Insulin Resistance: Is it Prevalent in Egyptian Patients with Rheumatoid Arthritis? J Autoimmune dis Rheum (2015) Vol 3, No 1. Olama Open Journal Systems.

42. El Sayed AM, El Bakry SA, Mobasher SA, Abd El Rahman R, Abo-Shady RA, Abaza N. Insulin resistance as a risk factor for subclinical Atherosclerosis in Rheumatoid Arthritis. The Egyptian Rheumatologist (2014) 36, 7–13.

43. Dessein PH1, Joffe BI. Insulin resistance and impaired beta cell function in rheumatoid arthritis. Arthritis Rheum. 2006 Sep;54(9):2765-75.

44. Giles JT1, Danielides S, Szklo M, Post WS, Blumenthal RS, et al. Insulin Resistance in Rheumatoid Arthritis Disease-Related Indicators and Associations with the Presence and Progression of Subclinical Atherosclerosis. Arthritis Rheumatol. 2015 Mar;67(3):626-36. doi: 10.1002/art.38986.

45. Liao KP, Cai T, Gainer VS, Cagan A, Murphy SN, Liu C, et al. Lipid and lipoprotein levels and trend in rheumatoid arthritis compared to the general population. Arthritis Care Res. 2013;65:2046–50.

46. Myasoedova E, Crowson CS, Kremers HM, Fitz-Gibbon PD, Therneau TM, Gabriel SE. Total cholesterol and LDL levels decrease before rheumatoid arthritis. Ann Rheum Dis. 2010;69:1310–4.

47. Liao KP, Liu J, Lu B1, Solomon DH, Kim SC. Association Between Lipid Levels and Major Adverse Cardiovascular Events in Rheumatoid Arthritis Compared to Non–Rheumatoid Arthritis Patients. Arthritis Rheumatol. 2015 May;67(8):2004-10. doi: 10.1002/art.39165.

48. Steiner G, Urowitz MB. Lipid Profiles in Patients with Rheumatoid Arthritis: Mechanisms and the Impact of Treatment. Semin Arthritis Rheum. 2009 Apr;38(5):372-81.

doi: 10.1016/j.semarthrit.2008.01.015

Abstract

References

Corresponding Author

Call For Paper Volume 12 Issue 12 December 2024

JMSCR Menu

Impact Factor SJIF 2024: 7.892

Crossref - DOI

Editorial Policy

Frequency of Publication

Submission of Articles

Search